Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review

Kaltschmidt B, Witte K, Greiner J, Weissinger F, Kaltschmidt C (2022)
Biomedicines 10(2): 261.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 10.79 MB
Abstract / Bemerkung
Among the cell populations existing within a tumor, cancer stem cells are responsible for metastasis formation and chemotherapeutic resistance. In the present review, we focus on the transcription factor NF-κB, which is present in every cell type including cancer stem cells. NF-κB is involved in pro-tumor inflammation by its target gene interleukin 1 (IL1) and can be activated by a feed-forward loop in an IL1-dependent manner. Here, we summarize current strategies targeting NF-κB by chemicals and biologicals within an integrated cancer therapy. Specifically, we start with a tyrosine kinase inhibitor targeting epidermal growth factor (EGF)-receptor-mediated phosphorylation. Furthermore, we summarize current strategies of multiple myeloma treatment involving lenalidomide, bortezomib, and dexamethasone as potential NF-κB inhibitors. Finally, we discuss programmed death-ligand 1 (PD-L1) as an NF-κB target gene and its role in checkpoint therapy. We conclude, that NF-κB inhibition by specific inhibitors of IκB kinase was of no clinical use but inhibition of upstream and downstream targets with drugs or biologicals might be a fruitful way to treat cancer stem cells.
Stichworte
cancer stem cells; NF-κB; EGF; PD-L1; lenalidomide; bortezomib; dexamethason
Erscheinungsjahr
2022
Zeitschriftentitel
Biomedicines
Band
10
Ausgabe
2
Art.-Nr.
261
eISSN
2227-9059
Finanzierungs-Informationen
Open-Access-Publikationskosten wurden durch die Universität Bielefeld gefördert.
Page URI
https://pub.uni-bielefeld.de/record/2960810

Zitieren

Kaltschmidt B, Witte K, Greiner J, Weissinger F, Kaltschmidt C. Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines. 2022;10(2): 261.
Kaltschmidt, B., Witte, K., Greiner, J., Weissinger, F., & Kaltschmidt, C. (2022). Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines, 10(2), 261. https://doi.org/10.3390/biomedicines10020261
Kaltschmidt, B., Witte, K., Greiner, J., Weissinger, F., and Kaltschmidt, C. (2022). Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines 10:261.
Kaltschmidt, B., et al., 2022. Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines, 10(2): 261.
B. Kaltschmidt, et al., “Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review”, Biomedicines, vol. 10, 2022, : 261.
Kaltschmidt, B., Witte, K., Greiner, J., Weissinger, F., Kaltschmidt, C.: Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines. 10, : 261 (2022).
Kaltschmidt, Barbara, Witte, Kaya, Greiner, Johannes, Weissinger, Florian, and Kaltschmidt, Christian. “Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review”. Biomedicines 10.2 (2022): 261.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2022-01-27T07:32:13Z
MD5 Prüfsumme
710a67d432c39acd926b4250df36e911

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 35203471
PubMed | Europe PMC

Suchen in

Google Scholar